Annexon, Inc.
NEWS
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
An improvement in cUHDRS was observed in more than half of all evaluable patients and was specifically seen in 75% of the evaluable population who showed excess complement activity at baseline.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Annexon, based in South San Francisco, closed on a $100 million Series C financing led by Redmile Group.
Biotech and pharma companies strengthen their leadership teams with new appointments.
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
JOBS
IN THE PRESS